Latest news with #Yesafili
Mint
12-05-2025
- Business
- Mint
Biocon to evaluate merger with subsidiary Biologics
Biocon Group's board is setting up a committee to evaluate strategic restructuring options, including a merger of its biosimilars arm Biocon Biologics Ltd with its flagship Biocon Ltd. The options would be evaluated taking into consideration matters relating to legal and tax aspects and subject to all approvals, including regulatory, board and shareholders, the company said in a release dated 8 May. The company had said in February that it would likely list its biosimilars business on the stock exchanges by March 2026. Also read: Biocon share price jumps 4% as subsidiary secures market entry for Yesafili in US '…given the market volatility that we are seeing on the IPO front, the board was of the opinion that we should look at other strategic options which also be includes evaluating a merger," Kiran Mazumdar-Shaw, chairperson, Biocon Group, told investors in an earnings call on Friday. "So at this point in time the board has constituted a committee, we will evaluate all strategic options and then get back to you in a few months with what the committee recommends to the board," she added. Biocon's board also approved raising up to ₹4,500 crore by way of issue of securities via qualified institutional placements, rights issue or other permissible routes, the company said. The funds will be used for repaying borrowings by the company or its subsidiaries, fulfilling other debt obligations, as well as investments in subsidiaries. Also read: All India Chemists and Druggists association urges members to ensure adequate stock supplies in border states Biocon Biologics acquired US drugmaker Viatris' global biosimilars business in 2022 to expand its global footprint. The company's CEO and managing director Shreehas Tambe had previously said it would consider an IPO after it completed the integration of the Viatris portfolio. 'On a full-year basis, the company has recorded a strong 15% growth in FY25 and we have successfully consolidated our business worldwide," Tambe said in the release. 'Having built a strong foundation, we are well-positioned to launch 5 new products in the next 12-18 months and expand patient access." Biocon is a global biopharmaceuticals company which has developed and commercialised novel biologics, biosimilars and complex small molecule active pharma ingredients (APIs) in India and several key global markets, as well as generic formulations in the US, Europe and emerging markets. The company is focused on complex therapies in chronic segments like diabetes, cancer and autoimmune. Also read: Donald Trump announces 59% cuts in US prescription drug prices, one day after new pharma policy Biocon Biologics' four biosimilars recorded sales of $200 million each in FY25. The company also launched its fifth biosimilar product, Yesinket (Ustekinumab), in the US in FY25.
Business Upturn
08-05-2025
- Business
- Business Upturn
Biocon Q4FY25 results: Net profit jumps 153% YoY to Rs 344 crore; revenue rises 12% to Rs 4,454 crore
By News Desk Published on May 8, 2025, 19:50 IST Biocon Limited reported a strong financial performance for the quarter and financial year ended March 31, 2025. For Q4FY25, consolidated revenue came in at Rs 4,454 crore, marking a 12% year-on-year (YoY) increase. On a like-for-like basis, the revenue grew 15% YoY after adjusting for revenues from Branded Formulations India (BFI). EBITDA rose 16% YoY to Rs 1,115 crore with an EBITDA margin of 25%. Core EBITDA, excluding R&D and other adjustments, came in at Rs 1,363 crore with a margin of 31%. The company posted a net profit of Rs 344 crore in Q4FY25, a significant 153% YoY jump. On a like-for-like basis, the net profit rose 162% YoY. Profit before tax (PBT) surged 53% YoY to Rs 487 crore. Segmental performance Generics : Revenue rose 46% YoY to Rs 1,048 crore, driven by strong contributions from Lenalidomide and Dasatinib launches in the U.S. : Revenue rose 46% YoY to Rs 1,048 crore, driven by strong contributions from Lenalidomide and Dasatinib launches in the U.S. Biosimilars : Revenue increased 4% YoY to Rs 2,463 crore. On an adjusted basis, it rose 9% YoY. : Revenue increased 4% YoY to Rs 2,463 crore. On an adjusted basis, it rose 9% YoY. Research Services (Syngene): Revenue climbed 11% YoY to Rs 1,018 crore. Full-year FY25 highlights For the full year, Biocon reported: Total revenue : Rs 16,470 crore, up 5% YoY (8% like-for-like) : Rs 16,470 crore, up 5% YoY (8% like-for-like) EBITDA : Rs 4,374 crore, up 5% YoY : Rs 4,374 crore, up 5% YoY Net profit: Rs 1,013 crore, down 1% YoY; however, like-for-like net profit increased 30% Dividend and capital plans The Board recommended a final dividend of Rs 0.50 per share. Additionally, it approved raising up to Rs 4,500 crore through various financial instruments for debt repayment and strategic investments. Strategic developments Biocon Biologics launched its fifth biosimilar, Yesintek (bUstekinumab), in the U.S. and Germany, and secured a U.S. market entry for Yesafili (bAflibercept). The company also partnered with Civica Inc. to increase access to insulins. Syngene crossed Rs 1,000 crore in quarterly revenue for the first time and acquired a biologics manufacturing facility in the U.S., expanding its CDMO capabilities. Biocon has also initiated an evaluation of a potential merger between Biocon Limited and Biocon Biologics. Sustainability Biocon and Biocon Biologics were both included in the S&P Global Sustainability Yearbook 2025, with Biocon ranked among the top 5% in the Biotechnology sector. News desk at
Deccan Herald
23-04-2025
- Business
- Deccan Herald
Biocon approves plan to raise $527 million
Recently, Biocon Biologics had inked a settlement and licensing pact with Regeneron, paving the way to commercialise its biosimilar product Yesafili in the US.
